- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZD8895 | COV2-2196
Compound class: Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 . It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab, is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised.
1. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS et al.. (2020)
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Nature, 584 (7821): 443-449. [PMID:32668443]